Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 10/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5767324 | 0.93 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL351651 | 0.89 | SMN1; SMN2 (0.73) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL12293978 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL5141180 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL5077235 | 0.86 | NPC1 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL14313091 | 0.86 | NPC1 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL4944408 | 0.86 | NPC1 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL31170113 | 0.85 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL31528425 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL23539139 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522618-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INST (US) | 2024-11-07 | — | — | US | disclosed |
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2024-06-18 | — | — | US | disclosed |
| EP-4204399-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS Therapy Development Institute (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116234800-A | Copper complexes for the treatment of neurodegenerative disorders | ALS治疗发展学会 | 2023-06-06 | — | — | CN | disclosed |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE, | 2023-02-23 | — | — | US | disclosed |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE, | 2023-02-23 | — | — | US | disclosed |
| WO-2022047014-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | MERCK SHARP & DOHME LLC | 2004-09-09 | — | — | US | disclosed |
| EP-1399160-A4 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO INC (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1414443-A1 | BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES | Merck & Co., Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| EP-1399160-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | Merck & Co., Inc. (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1379520-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003011285-A1 | BENZIMIDAZO[4,5-f]ISOQUINOLINONE DERIVATIVES | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2002100352-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO., INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK SHARP & DOHME LLC | 2002-11-07 | — | — | US | disclosed |
| WO-2002068409-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| US-5521199-A | TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176601-A1 | Benzimisazo[4,5-f]isoquinolinone derivatives | JAK1, JAK3, JAK2 | SMN1; SMN2 4534/4885NPC1 4071/4885RAB9A 1857/4885 |
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | SOD1, SMN1; SMN2, CLN6 | SMN1; SMN2 2/4885NPC1 329/4885RAB9A 947/4885 |
| US-20230054997-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | SMN1; SMN2 2/4885NPC1 329/4885RAB9A 947/4885 |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | SMN1; SMN2 2/4885NPC1 329/4885RAB9A 947/4885 |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | GRIN1, GRIN2B, GRIN2A | SMN1; SMN2 505/4885NPC1 1808/4885RAB9A 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.